Onconetix, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Onconetix, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 34,956% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-396.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in United States.
Cash Cushion Ratio
2.4× cashCash, after subtracting all debt, is 2.4 times its market value (net cash).
Higher than 96% of Healthcare companies in United States.
Tangible Assets Ratio
26%Of every $100 the company owns, $26 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 96% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 79% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Onconetix, Inc. owes $0.18 for every $1 it owns. Onconetix, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.0Investors pay $0.0 for every $1 of Onconetix, Inc.'s yearly profit, lower than almost all Healthcare companies in United States.
P/B ratio
0.16The share price is 0.16 times Onconetix, Inc.'s book value per share, lower than almost all Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Onconetix, Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$13 MWhat Onconetix, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.57Net worth divided by the number of shares. The share price of $0.41 is 0.2 times this, which is the P/B above.
Return on equity (ROE)
-105.2%Onconetix, Inc. lost 105.2% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
Owes vs Owns
0.18×Onconetix, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Dividend yield
NoneOnconetix, Inc. does not currently pay a dividend.
Revenue growth
-68%Revenue fell 68% in the year to Dec 2025.
Profit growth
LossOnconetix, Inc. made a loss in each of the last two years.
Profit margin
-1721.0%Onconetix, Inc. lost $1721 for every $100 of revenue.
Interest cover
Not coveredOnconetix, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashOnconetix, Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
What is Onconetix, Inc.'s P/E ratio?
Investors pay $0.0 for every $1 of Onconetix, Inc.'s yearly profit, lower than almost all Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Onconetix, Inc.: $2 M ÷ $13 M (30 Jun 2026) = 0.2.
What is Onconetix, Inc.'s return on equity?
Onconetix, Inc. lost 105.2% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
How much does Onconetix, Inc. owe compared with what it owns?
Onconetix, Inc. owes $0.18 for every $1 it owns (low), lower than 76% of Healthcare companies in United States.
Does Onconetix, Inc. pay a dividend?
No. Onconetix, Inc. does not currently pay a dividend.
Is Onconetix, Inc.'s revenue growing?
Revenue fell 68% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.